Motivation letter and tentative program

Translation of nanomedicines innovation from the laboratory to the clinic is a challenging process. Understanding and navigating the regulatory environment is critical for successful translation of nanomedicines.

I would like to bring to the nanomedicine community my experience (and network of international contacts) on identifying, addressing and solving issues on regulatory sicience, especially on the quality attributes of nanomedicines and the need (and state of play) for harmonization and standardization of measurements. The work of the "mRNA vaccines" and "nanomedicines" working groups of the European Pharmacopeia, and the previous work of the European Union Nanomedicine Characterization Lab (EUNCL) are particularly relevant in this context. I would like to use this opportunity to highlight their results and to use as examples for increase the engagement of the nanomedicine community with regulatory agencies and standardization organizations.